Good amycretin data. It looks like it will be able to break the 25% weight loss psychological barrier. The one cagrisema missed and sent Novo down 30%
Reposted from
Paul Bonanos
Novo Nordisk gets premarket bump (+11.5% at this moment) on NYSE. Ph1b/2a data show amycretin, its GLP-1/amylin agonist, led to dose-dependent weight loss of up to 22% at 36 weeks. "Vast majority" of GI effects were mild to moderate. www.novonordisk.com/news-and-med...
Comments